Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Audhuy

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Pathologie-Biologie|May 13, 2006
[A cytological, immunophenotypical and cytogenetical study of 136 consecutive cases of B-cell chronic lymphoid hemopathies]S Struski, V Leymarie, C Helias, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|March 29, 2002
Tumor necrosis factor alpha release is a major biological event associated with rituximab treatmentJ Bienvenu, R Chvetzoff, G Salles, et al.
Blood|August 15, 1996
Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter studyE Solary, B Witz, D Caillot, et al.
British Journal of Cancer|October 3, 1999
First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial)P Viens, T Palangié, M Janvier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2000
Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues MyeloblastiquesJ L Harousseau, B Witz, B Lioure, et al.
British Journal of Cancer|May 17, 2007
Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trialP Kerbrat, H Roché, J Bonneterre, et al.
British Journal of Haematology|August 1, 1996
Treatment of acute myelogenous leukaemia in patients aged 50-65: idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course. The Goelam GroupB Pignon, F Witz, B Desablens, et al.
Blood|November 5, 1997
Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM)J L Harousseau, J Y Cahn, B Pignon, et al.
Blood|May 16, 1998
A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM)F Witz, A Sadoun, M C Perrin, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Pathologie-Biologie|May 13, 2006
[A cytological, immunophenotypical and cytogenetical study of 136 consecutive cases of B-cell chronic lymphoid hemopathies]S Struski, V Leymarie, C Helias, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|March 29, 2002
Tumor necrosis factor alpha release is a major biological event associated with rituximab treatmentJ Bienvenu, R Chvetzoff, G Salles, et al.
Blood|August 15, 1996
Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter studyE Solary, B Witz, D Caillot, et al.
British Journal of Cancer|October 3, 1999
First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial)P Viens, T Palangié, M Janvier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2000
Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues MyeloblastiquesJ L Harousseau, B Witz, B Lioure, et al.
British Journal of Cancer|May 17, 2007
Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trialP Kerbrat, H Roché, J Bonneterre, et al.
British Journal of Haematology|August 1, 1996
Treatment of acute myelogenous leukaemia in patients aged 50-65: idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course. The Goelam GroupB Pignon, F Witz, B Desablens, et al.
Blood|November 5, 1997
Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM)J L Harousseau, J Y Cahn, B Pignon, et al.
Blood|May 16, 1998
A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM)F Witz, A Sadoun, M C Perrin, et al.
Pageof 5